Table 4.
Treatment patterns among patients with metastatic NSCLC with a subsequent therapy
| Subsequent therapy | Patients who received 1 L EGFR-TKI and had subsequent therapy | Patients who received 2 L+ EGFR-TKI and had subsequent therapy |
|---|---|---|
| (N = 160) | (N = 134) | |
| Chemotherapy alone, n (%) | 25 (15.6) | 29 (21.6) |
| Immunotherapy alone, n (%) | 22 (13.8) | 55 (41.0) |
| Targeted therapies n (%)a | 112 (70.0) | 49 (36.6) |
| EGFR-TKIb | 102 (63.8) | 33 (24.6) |
| Continued on/switched to another 1st/2nd gen. EGFR-TKI | 62 (38.8) | 27 (20.1) |
| Afatinib | 33 (20.6) | 11 (8.2) |
| Erlotinib | 17 (10.6) | 13 (9.7) |
| Gefitinib | 13 (8.1) | 5 (3.7) |
| Osimertinibc | 40 (25.0) | 7 (5.2) |
| Other targeted therapiesd | 10 (6.3) | 16 (11.9) |
| Clinical study drug, n (%) | 1 (0.6) | 1 (0.7) |
1 L first line, 2 L+ second or later line, ALK anaplastic lymphoma kinase EGFR epidermal growth factor receptor, EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor, NSCLC non-small cell lung cancer
a Patients could have received targeted therapies alone or in combination with chemotherapy and/or immunotherapy
b Four patients had more than one EGFR-TKI as a subsequent therapy. Hence, the sum of the individual EGFR-TKIs (i.e. afatinib, erlotinib, geftinib, and osimertinib) will be greater than the total number who received EGFR-TKI
c Of the 47 patients who received osimertinib as subsequent therapies, 24 were tested T790M positive, seven were not positive for T790M, and 16 were not tested for EGFR mutations
d Other targeted therapeutic agents are listed in Table 1